In agreement with a previous meta-analysis, that was conducted on DPP-4 inhibitors including four studies on alogliptin, [27] this meta-analysis has demonstrated a significant reduction of HbA1c ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...